Drug Profile
Research programme: anticancer monoclonal antibodies - Precision Biologics
Alternative Names: 31.1 antibody; 31.1 monoclonal antibody; NEO-301; Sq-1; Sq-2Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Neogenix Oncology
- Developer Precision Biologics
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Neoplasm antigen inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Colorectal cancer; Pancreatic cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Colorectal-cancer in USA (Parenteral)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Pancreatic-cancer in USA (Parenteral)
- 17 Apr 2013 Precision Biologics is conducting preclinical development of anticancer monoclonal antibodies in USA